We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+16.46%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$119M
AUM Growth
+$18.2M
Cap. Flow
+$7.39M
Cap. Flow %
6.19%
Top 10 Hldgs %
33.76%
Holding
75
New
17
Increased
23
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$3.55M
2
ALKS icon
Alkermes
ALKS
+$2.93M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$2.05M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.98M
5
NKTR icon
Nektar Therapeutics
NKTR
+$1.35M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.88M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$3.03M
3
PCYC
PHARMACYCLICS INC
PCYC
+$2.34M
4
UTHR icon
United Therapeutics
UTHR
+$2.11M
5
AMGN icon
Amgen
AMGN
+$1.91M

Sector Composition

Rank Sector Weight
1 Healthcare 76.66%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$4.23M 3.55%
25,679
+2,708
+12% +$343K
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$4.16M 3.48%
55,988
+28,988
+107% +$2.05M
SLXP
3
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$4.15M 3.48%
24,000
+5,813
+32% +$853K
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.9B
$4.06M 3.4%
32,545
-11,186
-26% -$1.19M
INCY icon
5
Incyte
INCY
$25.4B
$4M 3.36%
43,682
-17,195
-28% -$1.42M
MDVN
6
DELISTED
MEDIVATION, INC.
MDVN
$3.97M 3.33%
61,494
-1,260
-2% -$72.2K
REGN icon
7
Regeneron Pharmaceuticals
REGN
$72.9B
$3.95M 3.31%
8,750
+100
+1% +$42.4K
BIIB icon
8
Biogen
BIIB
$30.9B
$3.94M 3.3%
9,331
-155
-2% -$61.1K
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$3.93M 3.29%
111,050
+28,797
+35% +$982K
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$38.3B
$3.9M 3.27%
37,388
+19,513
+109% +$1.98M
IONS icon
11
Ionis Pharmaceuticals
IONS
$8.93B
$3.88M 3.25%
60,912
+15,494
+34% +$1.05M
VRTX icon
12
Vertex Pharmaceuticals
VRTX
$123B
$3.87M 3.24%
32,805
+3,709
+13% +$444K
CELG
13
DELISTED
Celgene Corp
CELG
$3.84M 3.22%
33,289
+249
+0.8% +$29.8K
ILMN icon
14
Illumina
ILMN
$29.5B
$3.83M 3.21%
21,186
+2,277
+12% +$429K
ALXN
15
DELISTED
Alexion Pharmaceuticals
ALXN
$3.82M 3.2%
22,031
+3,699
+20% +$670K
ALKS icon
16
Alkermes
ALKS
$8.11B
$3.81M 3.2%
62,546
+42,915
+219% +$2.93M
NKTR icon
17
Nektar Therapeutics
NKTR
$2.39B
$3.69M 3.09%
22,377
+6,570
+42% +$1.35M
PCYC
18
DELISTED
PHARMACYCLICS INC
PCYC
$3.48M 2.92%
13,600
-12,123
-47% -$2.34M
CPHD
19
DELISTED
Cepheid Inc
CPHD
$3.11M 2.61%
54,693
-5,693
-9% -$320K
PCRX icon
20
Pacira BioSciences
PCRX
$1.04B
$3.1M 2.6%
+34,949
New +$3.55M
MTD icon
21
Mettler-Toledo International
MTD
$28.1B
$3.1M 2.6%
9,436
-564
-6% -$175K
TECH icon
22
Bio-Techne
TECH
$11.2B
$3.1M 2.6%
123,668
+12,068
+11% +$287K
QGENF
23
DELISTED
QIAGEN NV
QGENF
$3.09M 2.59%
122,724
+8,724
+8% +$220K
BIB icon
24
ProShares Ultra NASDAQ Biotechnology
BIB
$82.9M
$2.82M 2.36%
35,568
-40,800
-53% -$3.03M
GEVA
25
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$1.73M 1.45%
17,700
-2,302
-12% -$244K
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q1 2015 Portfolio in Review

As of Q1 2015, Opus Point Partners Management held 75 positions worth $119M, up 18% from $101M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Opus Point Partners Management deployed $7.39M of net new capital in Q1 2015, opening 17 new positions and adding to 23 existing holdings. Its largest new stake was Pacira BioSciences: 34,949 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 70% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was ProShares Ultra NASDAQ Biotechnology, an estimated $3.03M trimmed.

  • Opus Point Partners Management's largest Q1 2015 buy was Pacira BioSciences: 34,949 shares worth $3.1M.
  • Opus Point Partners Management added most to Alkermes in Q1 2015, an estimated $2.93M increase.
  • Opus Point Partners Management's biggest Q1 2015 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $3.03M.
  • Opus Point Partners Management fully exited State Street SPDR S&P Biotech ETF in Q1 2015, selling an estimated $3.88M.
  • Opus Point Partners Management's ten largest holdings make up 34% of its $119M portfolio in Q1 2015.
  • Opus Point Partners Management opened 17 new positions and closed 10 in Q1 2015.
  • Opus Point Partners Management's portfolio value rose 18% quarter-over-quarter to $119M.

Based on Opus Point Partners Management's 13F filing for Q1 2015, filed 18 May 2015.